GLUE short interest
Monte Rosa Therapeutics Inc. · Healthcare · Biotechnology · settlement date 2026-09-30
| Shares short | 19,686,241 |
|---|---|
| Change vs prior report | 420,251 (+2.2%) |
| Change over six months | +46.9% |
| Days to cover | 18.00 (sector: 3.78) |
| Average daily volume | 1,093,381 |
| Rank in Healthcare | #22 of 922 by days to cover |
GLUE short interest, last 12 months
| Settlement | Shares short | Change | Days to cover | Avg daily volume |
|---|---|---|---|---|
| 2026-09-30 | 19,686,241 | +2.2% | 18.00 | 1,093,381 |
| 2026-09-15 | 19,265,990 | +6.6% | 17.08 | 1,127,772 |
| 2026-08-31 | 18,075,786 | +3.5% | 16.56 | 1,091,293 |
| 2026-08-14 | 17,457,317 | +6.1% | 13.99 | 1,247,991 |
| 2026-07-31 | 16,458,543 | -4.3% | 10.59 | 1,554,197 |
| 2026-07-15 | 17,195,471 | -7.7% | 13.08 | 1,314,790 |
| 2026-06-30 | 18,634,735 | +8.5% | 8.49 | 2,195,951 |
| 2026-06-15 | 17,170,729 | +7.3% | 16.62 | 1,033,043 |
| 2026-05-29 | 16,005,122 | +7.0% | 19.21 | 832,953 |
| 2026-05-15 | 14,962,299 | -1.2% | 20.63 | 725,334 |
| 2026-04-30 | 15,142,638 | -4.4% | 17.85 | 848,528 |
| 2026-04-15 | 15,837,633 | +18.2% | 15.99 | 990,243 |
| 2026-03-31 | 13,398,925 | +22.2% | 8.81 | 1,520,828 |
| 2026-03-13 | 10,964,393 | +8.4% | 12.64 | 867,615 |
| 2026-02-27 | 10,115,500 | +8.4% | 10.70 | 945,395 |
| 2026-02-13 | 9,330,612 | +21.8% | 9.28 | 1,005,178 |
| 2026-01-30 | 7,664,016 | +38.0% | 6.73 | 1,138,207 |
| 2026-01-15 | 5,554,802 | -34.3% | 1.37 | 4,043,321 |
| 2025-12-31 | 8,454,052 | +20.8% | 5.79 | 1,459,903 |
| 2025-12-15 | 7,001,428 | -0.1% | 9.46 | 739,854 |
| 2025-11-28 | 7,006,369 | -5.3% | 8.62 | 812,508 |
| 2025-11-14 | 7,396,896 | -7.4% | 6.80 | 1,087,763 |
| 2025-10-31 | 7,988,754 | -1.2% | 7.64 | 1,045,303 |
| 2025-10-15 | 8,082,854 | +3.2% | 5.96 | 1,355,619 |
| 2025-09-30 | 7,831,770 | -5.0% | 5.75 | 1,362,952 |
import finzdata as yf
yf.Ticker("GLUE").short_interest # every report since 2017
yf.Client().short_interest(["GLUE"], start="2018-01-01")Healthcare short interest · GLUE price history · Who owns GLUE · All short interest